Stockscreener 앱 받기
20.16
6.28%
-1.35
시간 외 거래:
19.57
-0.59
-2.93%
전일 마감가:
$21.51
열려 있는:
$21.27
하루 거래량:
1.05M
Relative Volume:
1.83
시가총액:
$722.84M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+43.69%
1개월 성능:
+61.15%
6개월 성능:
+335.42%
1년 성능:
+300.00%
1일 변동 폭
$19.72
$21.27
1주일 범위
$14.90
$24.00
52주 변동 폭
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
BIOA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
20.16 | 771.24M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors (NASDAQ:BIOA) - Seeking Alpha
The JPM Effect In Short Supply But BioAge And Bayer Gain - Citeline News & Insights
Bioage Labs Inc (BIOA) Stock Price Down 5.15% on Jan 16 - GuruFocus
Insider Selling: CEO Kristen Fortney Sells Shares of Bioage Labs Inc (BIOA) - GuruFocus
Insider Selling: BioAge Labs (NASDAQ:BIOA) CEO Sells 233,107 Shares of Stock - MarketBeat
Dov Md Goldstein Sells 27,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
Bioage Labs Insider Sold Shares Worth $4,223,036, According to a Recent SEC Filing - marketscreener.com
Bioage Labs Insider Sold Shares Worth $531,828, According to a Recent SEC Filing - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Shares Up 7.1%Time to Buy? - MarketBeat
BioAge Labs extends rally after updating early-stage trial data for lead drug - Seeking Alpha
BioAge reports 86% reduction in inflammation markers with BGE-102 By Investing.com - Investing.com India
BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year HighShould You Buy? - MarketBeat
BioAge stock soars 21% on positive data for inflammation drug By Investing.com - Investing.com South Africa
BioAge stock soars 21% on positive data for inflammation drug - Investing.com
BioAge Labs advances BGE-102 with strong Phase 1 data - TipRanks
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets
BioAge announces additional positive interim phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk - marketscreener.com
Experimental pill sharply cuts heart inflammation in 2 weeks - Stock Titan
Institutional investors are BioAge Labs, Inc.'s (NASDAQ:BIOA) biggest bettors and were rewarded after last week's US$51m market cap gain - simplywall.st
Weekly Earnings: Will The Chemours Company 2CU stock benefit from sector leadershipWeekly Trading Summary & Safe Capital Growth Plans - Bộ Nội Vụ
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Reactions & Fast Exit Strategy with Risk Control - Улправда
Can BioAge Labs Inc. stock deliver sustainable ROERelative Strength Index (RSI) & Individual Stock Tracking Service - bollywoodhelpline.com
Aug Ideas: Will BioAge Labs Inc. stock maintain growth storyRate Hike & Target Return Focused Stock Picks - Улправда
How analysts rate BioAge Labs Inc. stock todayJuly 2025 News Drivers & Reliable Momentum Entry Alerts - Улправда
Is BioAge Labs Inc. (Y7G) stock included in top ETFs2025 Pullback Review & Low Drawdown Momentum Trade Ideas - ulpravda.ru
What MACD trends signal for BioAge Labs Inc. (Y7G) stockQuarterly Risk Review & Verified Swing Trading Watchlist - Улправда
Why BioAge Labs Inc. stock could outperform in 20252025 Volume Leaders & Reliable Volume Spike Trade Alerts - Улправда
Aug Selloffs: Will BioAge Labs Inc. stock gain from lower inflationWeekly Profit Analysis & Scalable Portfolio Growth Methods - Улправда
BioAge Labs Hits New 52-Week High; Next Key Catalyst Due In 1H 2026 - RTTNews
BioAge Labs (NASDAQ:BIOA) Hits New 12-Month HighTime to Buy? - MarketBeat
BioAge Labs upgraded to equal weight from underweight at Morgan Stanley - MSN
BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile
BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat
Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets
BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com
BioAge Labs announces positive phase 1 trial results - MSN
BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq
Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber
What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber
Bioage Labs Earnings Notes - Trefis
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
Bioage Labs Inc (BIOA) 재무 분석
Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bioage Labs Inc 주식 (BIOA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Jan 13 '26 |
Sale |
19.70 |
27,000 |
531,828 |
22,408 |
| Fortney Kristen | Chief Executive Officer |
Jan 13 '26 |
Sale |
18.12 |
233,107 |
4,223,036 |
976,949 |
1.30%
1.45%
자본화:
|
볼륨(24시간):